In the structure of the causes of morbidity and mortality in the neonatal period, the leading role is occupied by the pathology of the respiratory organs, which is associated with the morphofunctional characteristics of the respiratory system of the newborn child. The main role in the immunopathogenesis of the syndrome of respiratory disorders is assigned to proteins of pulmonary surfactant (SP-A,SP-D). The use of surfactant proteins as new molecular biomarkers will allow them to be used to improve the results of diagnosis and treatment of respiratory disorders in newborns of various gestational ages.
R.A. Polin, W. A. Carlo, // Surfactant replacement therapy for preterm and term neonates with respiratory distress // Guidance for the Clinician in Rendering Pediatric Care 2018,156-161
Свирская О.Я. Респираторная и сурфактантная терапия у недоношенных детей с асфиксией при рождении и респираторным дистресс синдромом. Автореферат диссертации на соискание ученой степени кандидата медицинских наук. Минск 2013.
Jason Gien, John P. Kinsella. // Pathogenesis and treatment of bronchopulmonary dysplasia // Curr Opin Pediatr. 2011 June ; 23(3): 305–313.
Шилова Н.А., Чаша Т.В., Попова И.Г., Хорошилова А.Г.// Клиническое значение исследования пневмопротеинов у глубоконедоношенных детей // Российский педиатрический журнал № 1. 2012.стр. 28-31.